4D Molecular Therapeutics Q3 EPS $(0.24) Beats $(0.54) Estimate, Sales $20.20K Miss $9.87M Estimate
Portfolio Pulse from Benzinga Newsdesk
4D Molecular Therapeutics (NASDAQ:FDMT) reported Q3 losses of $(0.24) per share, beating the analyst consensus estimate of $(0.54) by 55.56%. However, the company's quarterly sales of $20.20K missed the analyst consensus estimate of $9.87M by 99.80%, marking a 95.96% decrease from the same period last year.
November 09, 2023 | 11:41 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
4D Molecular Therapeutics reported better than expected Q3 EPS but significantly missed on sales.
While the company beat EPS estimates, the significant miss on sales could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100